These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 31700918

  • 21. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S, Shi YK, Liu P, Han XH, He XH, Cai YM, Chen ZM.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness analysis of mecapegfilgrastim and recombinant human granulocyte stimulating factor for primary prophylaxis of chemotherapy-induced neutropenia in non-small cell lung cancer.
    Gu YL, Sun ZX, Sun Y, Guan X, Jiang DL.
    Int J Clin Pharmacol Ther; 2024 Mar; 62(3):115-121. PubMed ID: 38263810
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
    Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A.
    Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
    Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G.
    Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
    Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I.
    Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
    [Abstract] [Full Text] [Related]

  • 32. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.
    Clin Ther; 2009 Jun; 31 Pt 2():2388-95. PubMed ID: 20110048
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.
    Hegg R, Mattar A, Matos-Neto JN, Pedrini JL, Aleixo SB, Rocha RO, Cramer-Junior RP, van-Eyll-Rocha S.
    Clinics (Sao Paulo); 2016 Oct 01; 71(10):586-592. PubMed ID: 27759847
    [Abstract] [Full Text] [Related]

  • 35. A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer.
    Mao C, He Y, Xu N, Yan H, Zhang N, Cheng G, Jiang H, Chen M, Chen Y, Wang X, Gu Y, Shen P, Zhang G, Yan J, Yang Z, Ding L, Han Z, Wang Z, Zhang J, Zheng W, Wang J, Qin S.
    Immun Inflamm Dis; 2024 Aug 01; 12(8):e1348. PubMed ID: 39105572
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z.
    Support Care Cancer; 2015 Feb 01; 23(2):525-45. PubMed ID: 25284721
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J.
    Curr Med Res Opin; 2011 Jan 01; 27(1):79-86. PubMed ID: 21091127
    [Abstract] [Full Text] [Related]

  • 40. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.
    J Oncol Pharm Pract; 2016 Oct 01; 22(5):702-16. PubMed ID: 26769697
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.